Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

• Published in: Advances in therapy 2022-08, Vol.39 (8), p.3799-3834
• Main Authors: Yang, Guangzhong, Geng, Chuanying, Jian, Yuan, Zhou, Huixing, Chen, Wenming
• Format: Article
• Language: English
• Subjects: Cardiology; Endocrinology; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Original Research; Pharmacology/Toxicology; Rheumatology
• ISSN: 0741-238X; 1865-8652
• DOI: 10.1007/s12325-022-02195-1

Introduction The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has become standard of care for transplant-eligible patients with newly diagnosed MM (NDMM). This study aimed to determine the efficacy of RVd as induction therapy in terms of response rates and survival outcomes of transplant-eligible patients with NDMM. Methods The databases of Medline, Embase, and Cochrane Library were searched until February 1, 2021. Both randomized controlled trials (RCT) and non-RCTs from the available literature were extracted as one-arm data to assess the efficacy of each triplet regimen for the target patients in terms of response rates and survival rates for transplant-eligible patients with NDMM. Data was summarized as estimated pooled value regarding each evaluated index. Risk of bias of studies was assessed with standard methods. Results The findings of 71 studies published from 2008 to 2020 were analyzed. For RVd induction, the overall response rate (ORR), very good partial response or better (≥ VGPR) rate, and complete response or better (≥ CR) rate after induction were 0.91 (95% CI 0.86–0.95), 0.23 (95% CI 0.17–0.29), and 0.56 (95% CI 0.51–0.61), respectively. Indirect comparisons in efficacy were made between RVd and other traditional triplet regimens. RVd induction led to a better ≥ CR rate than bortezomib, cyclophosphamide, and dexamethasone (VCd) regimen in both postinduction and post-ASCT phase, ≥ CR rate 0.11 (95% CI 0.08–0.15) and 0.21 (95% CI 0.12–0.32), respectively. The 1-year overall survival (OS) rate and 3-year OS rate of RVd regimen were longer than that of bortezomib, thalidomide, and dexamethasone (VTd), 0.97 (95% CI 0.94–0.98) vs 0.71 (95% CI 0.61–0.80), and 0.90 (95% CI 0.79–0.98) vs 0.70 (95% CI 0.64–0.75), respectively. Conclusions The RVd induction demonstrated confident response rates and survival benefits for transplant-eligible patients with NDMM.